Abstract
Purpose The COVID-19 pandemic has resulted in unprecedented circumstances and changes in behaviour. This research sought to better understand the impact of the COVID-19 pandemic, and lockdown, on smoking behaviour in the UK from the perspectives of consumers (current and former smokers) and some of their smoking-related behaviour-influencers.
Design/methodology/approach This research project encompassed two surveys, one for current and former smokers (Consumers) and one for those individuals in professions with the potential to influence smoking behaviours (Influencers). Both surveys were conducted online and were infield for approximately two weeks during UK’s first COVID-19 lockdown. Because of the unprecedented times the society was experiencing, several questions relating directly to COVID-19 were added to the survey and this paper is based only on findings only from those questions and not the whole project. The results were analysed descriptively.
Findings A total of 954 consumers and 1027 influencers participated in the surveys. Increased smoking was reported by 67% of the consumers mainly due to stress and boredom arising out of COVID-19 lockdown. Consumers under 45 years of age, those in professional and managerial occupations, and among dual users reported increased smoking in lockdown. The COVID-19 situation changed the plans to quit smoking in 36% of consumers, with only 6% deciding to quit. Only 40% of healthcare professionals (HCPs) documented patient smoking status in over half their interactions.
Originality/ value This research among current and former smokers and their influencers highlights important changes in behaviour during the COVID-19 times and underscores urgent measures to be taken by HCPs and policymakers for staying on course of achieving smokefree goals despite challenges posed by COVID-19.
Competing Interest Statement
Dr Sudhanshu Patwardhan (SP) is a paid Director at Centre for Health Research and Education (CHRE), an independent healthcare company which works on global smoking cessation and cancer prevention projects. CHRE has received grants from Foundation for a Smoke-free World, Inc for some of its smoking cessation projects, including towards this project. Previously, SP was an employee of Nicoventures, a wholly owned subsidiary of British American Tobacco, till February 2019. Ms Claudia Trainer (CT) is a paid employee at Ogilvy Consultings Behavioural Science Practice. CTs employer (Ogilvy UK, part of WPP plc) has provided consulting-type support on paid projects to tobacco companies, such as PMI, in the last 36 months. These projects aimed to identify ways of encouraging smokers to switch from cigarettes to reduced harm products. CT has not worked on these projects and has no direct relationships, personally or paid, with these companies.
Clinical Trial
This was not a clinical trial or a prospective study. It was a cross sectional survey without any intervention or clinical measurements. The individuals were assessed in this survey using a questionnaire.
Funding Statement
This paper is part of Centre for Health Research and Education (CHRE)s Smokefree UK project. CHRE is an independent healthcare company which works on global smoking cessation and cancer prevention projects. The project is conceptualised, designed, led and managed by CHRE. CHRE applied for and was awarded a grant from the Foundation for a Smoke-Free World, Inc (FSFW) for a part of the Smokefree UK project. The contents, selection, and presentation of facts, as well as any opinions expressed herein are the sole responsibility of the authors and under no circumstances shall be regarded as reflecting the positions of FSFW.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
It was confirmed with the UK Health Research Authority that HRA and HCRW Approval was not required for this study (Communication dated 1st May 2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data related to this project is available on the website: www.smoke-free.uk
